X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical candidates.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: $930.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 22, 2022
Details:
Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 22, 2022
Details:
Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical candidates.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: $930.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 22, 2022
Details:
AR-15512 is a first-in-class TRPM8 agonist which acts as a cold thermoreceptor modulator to stimulate the cold sensing receptors found on the nerve endings that innervate the cornea and eyelids.
Lead Product(s): AVX012
Therapeutic Area: Ophthalmology Product Name: AR-15512
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
AR-15512 (AVX012), is a first-in-class TRPM8 agonist which acts as a cold thermoreceptor modulator to stimulate the cold sensing receptors found on the nerve endings that innervate the cornea and eyelids.
Lead Product(s): AVX012
Therapeutic Area: Ophthalmology Product Name: AR-15512
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
The acquisition will complement Alcon’s existing portfolio in the large and fast-growing dry eye category. EYSUVIS (Loteprednol Etabonate) will complement the Systane® family of eye drops which includes the recently launched Systane Preservative-Free formulations.
Lead Product(s): Loteprednol Etabonate
Therapeutic Area: Ophthalmology Product Name: Eysuvis
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Kala Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $60.0 million
Deal Type: Acquisition May 23, 2022
Details:
Rocklatan (netarsudil and latanoprost), indicated for reduction of elevated IOP in patients with glaucoma or ocular hypertension, demonstrated consistent IOP reduction of ~9.5 mmHg and an average IOP reduction of 37% from baseline in European Phase 3B clinical trial.
Lead Product(s): Netarsudil
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rhopressa and Rocklatan.
Lead Product(s): Netarsudil
Therapeutic Area: Ophthalmology Product Name: Rhopressa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Santen Pharmaceutical
Deal Size: $168.0 million Upfront Cash: $88.0 million
Deal Type: Expanded Collaboration December 07, 2021
Details:
Netarsudil 0.02% is known by the name Rhokiinsa® in the European Union, where it is approved for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
Both formulations of AR-15512 were safe and well-tolerated. Ninety five percent of adverse events were mild with less than 3 percent of subjects discontinued due to adverse events.
Lead Product(s): AR-15512
Therapeutic Area: Ophthalmology Product Name: AVX012
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
